Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends

Michel Sabe; Toby Pillinger; Stefan Kaiser; Chaomei Chen; Heidi Taipale; Antti Tanskanen; Jari Tiihonen; Stefan Leucht; Christoph U. Correll; Marco Solmi

doi:10.1016/j.neubiorev.2022.104608

Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends

Michel Sabe^*, Toby Pillinger, Stefan Kaiser, Chaomei Chen, Heidi Taipale, Antti Tanskanen, Jari Tiihonen, Stefan Leucht, Christoph U. Correll, Marco Solmi

^*Corresponding author for this work

Psychosis Studies

Research output: Contribution to journal › Review article › peer-review

85 Citations (Scopus)

390 Downloads (Pure)

Abstract

Changes over 50 years of research on antipsychotics in schizophrenia have occurred. A scientometric synthesis of such changes over time and a measure of researchers' networks and scientific productivity is currently lacking. We searched Web of Science Core Collection from inception until November 5, 2021, using the appropriate key. Our primary objective was to conduct systematic mapping with CiteSpace to show how clusters of keywords have evolved over time and obtain clusters’ structure and credibility. Our secondary objective was to measure research network performance (countries, institutions, and authors) using CiteSpace, VOSviewer, and Bibliometrix. We included 32,240 studies published between 1955 and 2021. The co-cited reference network identified 25 clusters with a well-structured network (Q=0.8166) and highly credible clustering (S=0.91). The main trends of research were: 1) antipsychotic efficacy; 2) cognition in schizophrenia; 3) side effects of antipsychotics. Last five years research trends were: ‘ultra-resistance schizophrenia’ (S=0.925), ‘efficacy/dose-response’ (S=0.775), ‘evidence-synthesis’ (S=0.737), ‘real-world effectiveness’ (S=0.794), ‘cannabidiol’ (S=0.989), and ‘gut microbiome’ (S=0.842). These results can inform funding agencies and research groups' future directions.

Original language	English
Article number	104608
Journal	Neuroscience and Biobehavioral Reviews
Volume	136
Early online date	15 Mar 2022
DOIs	https://doi.org/10.1016/j.neubiorev.2022.104608
Publication status	E-pub ahead of print - 15 Mar 2022

Keywords

CiteSpace
Evidence synthesis
Meta-analysis
Psychosis
Scientometric
Systematic review

Access to Document

10.1016/j.neubiorev.2022.104608

Half a century of research_SABE_Published online 15 Mar 22_GOLD VoR (CC BY)Final published version, 15.1 MBLicence: CC BY

Cite this

Sabe, M., Pillinger, T., Kaiser, S., Chen, C., Taipale, H., Tanskanen, A., Tiihonen, J., Leucht, S., Correll, C. U., & Solmi, M. (2022). Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. Neuroscience and Biobehavioral Reviews, 136, Article 104608. Advance online publication. https://doi.org/10.1016/j.neubiorev.2022.104608

@article{879eb8bc55ce4d368818796f82d381e9,

title = "Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends",

abstract = "Changes over 50 years of research on antipsychotics in schizophrenia have occurred. A scientometric synthesis of such changes over time and a measure of researchers' networks and scientific productivity is currently lacking. We searched Web of Science Core Collection from inception until November 5, 2021, using the appropriate key. Our primary objective was to conduct systematic mapping with CiteSpace to show how clusters of keywords have evolved over time and obtain clusters{\textquoteright} structure and credibility. Our secondary objective was to measure research network performance (countries, institutions, and authors) using CiteSpace, VOSviewer, and Bibliometrix. We included 32,240 studies published between 1955 and 2021. The co-cited reference network identified 25 clusters with a well-structured network (Q=0.8166) and highly credible clustering (S=0.91). The main trends of research were: 1) antipsychotic efficacy; 2) cognition in schizophrenia; 3) side effects of antipsychotics. Last five years research trends were: {\textquoteleft}ultra-resistance schizophrenia{\textquoteright} (S=0.925), {\textquoteleft}efficacy/dose-response{\textquoteright} (S=0.775), {\textquoteleft}evidence-synthesis{\textquoteright} (S=0.737), {\textquoteleft}real-world effectiveness{\textquoteright} (S=0.794), {\textquoteleft}cannabidiol{\textquoteright} (S=0.989), and {\textquoteleft}gut microbiome{\textquoteright} (S=0.842). These results can inform funding agencies and research groups' future directions.",

keywords = "CiteSpace, Evidence synthesis, Meta-analysis, Psychosis, Scientometric, Systematic review",

author = "Michel Sabe and Toby Pillinger and Stefan Kaiser and Chaomei Chen and Heidi Taipale and Antti Tanskanen and Jari Tiihonen and Stefan Leucht and Correll, {Christoph U.} and Marco Solmi",

note = "Funding Information: Toby Pillinger is supported by the National Institute for Health Research (NIHR) and Maudsley Charity. Funding Information: Jari Tiihonen, Antti Tanskanen and Heidi Taipale have participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to their employing institution. Funding Information: Christoph U. Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Rovi, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of LB Pharma. Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = mar,

day = "15",

doi = "10.1016/j.neubiorev.2022.104608",

language = "English",

volume = "136",

journal = "Neuroscience and Biobehavioral Reviews",

issn = "0149-7634",

}

TY - JOUR

T1 - Half a century of research on antipsychotics and schizophrenia

T2 - A scientometric study of hotspots, nodes, bursts, and trends

AU - Sabe, Michel

AU - Pillinger, Toby

AU - Kaiser, Stefan

AU - Chen, Chaomei

AU - Taipale, Heidi

AU - Tanskanen, Antti

AU - Tiihonen, Jari

AU - Leucht, Stefan

AU - Correll, Christoph U.

AU - Solmi, Marco

N1 - Funding Information: Toby Pillinger is supported by the National Institute for Health Research (NIHR) and Maudsley Charity. Funding Information: Jari Tiihonen, Antti Tanskanen and Heidi Taipale have participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to their employing institution. Funding Information: Christoph U. Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Rovi, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of LB Pharma. Publisher Copyright: © 2022 The Authors

PY - 2022/3/15

Y1 - 2022/3/15

N2 - Changes over 50 years of research on antipsychotics in schizophrenia have occurred. A scientometric synthesis of such changes over time and a measure of researchers' networks and scientific productivity is currently lacking. We searched Web of Science Core Collection from inception until November 5, 2021, using the appropriate key. Our primary objective was to conduct systematic mapping with CiteSpace to show how clusters of keywords have evolved over time and obtain clusters’ structure and credibility. Our secondary objective was to measure research network performance (countries, institutions, and authors) using CiteSpace, VOSviewer, and Bibliometrix. We included 32,240 studies published between 1955 and 2021. The co-cited reference network identified 25 clusters with a well-structured network (Q=0.8166) and highly credible clustering (S=0.91). The main trends of research were: 1) antipsychotic efficacy; 2) cognition in schizophrenia; 3) side effects of antipsychotics. Last five years research trends were: ‘ultra-resistance schizophrenia’ (S=0.925), ‘efficacy/dose-response’ (S=0.775), ‘evidence-synthesis’ (S=0.737), ‘real-world effectiveness’ (S=0.794), ‘cannabidiol’ (S=0.989), and ‘gut microbiome’ (S=0.842). These results can inform funding agencies and research groups' future directions.

AB - Changes over 50 years of research on antipsychotics in schizophrenia have occurred. A scientometric synthesis of such changes over time and a measure of researchers' networks and scientific productivity is currently lacking. We searched Web of Science Core Collection from inception until November 5, 2021, using the appropriate key. Our primary objective was to conduct systematic mapping with CiteSpace to show how clusters of keywords have evolved over time and obtain clusters’ structure and credibility. Our secondary objective was to measure research network performance (countries, institutions, and authors) using CiteSpace, VOSviewer, and Bibliometrix. We included 32,240 studies published between 1955 and 2021. The co-cited reference network identified 25 clusters with a well-structured network (Q=0.8166) and highly credible clustering (S=0.91). The main trends of research were: 1) antipsychotic efficacy; 2) cognition in schizophrenia; 3) side effects of antipsychotics. Last five years research trends were: ‘ultra-resistance schizophrenia’ (S=0.925), ‘efficacy/dose-response’ (S=0.775), ‘evidence-synthesis’ (S=0.737), ‘real-world effectiveness’ (S=0.794), ‘cannabidiol’ (S=0.989), and ‘gut microbiome’ (S=0.842). These results can inform funding agencies and research groups' future directions.

KW - CiteSpace

KW - Evidence synthesis

KW - Meta-analysis

KW - Psychosis

KW - Scientometric

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85126582169&partnerID=8YFLogxK

U2 - 10.1016/j.neubiorev.2022.104608

DO - 10.1016/j.neubiorev.2022.104608

M3 - Review article

AN - SCOPUS:85126582169

SN - 0149-7634

VL - 136

JO - Neuroscience and Biobehavioral Reviews

JF - Neuroscience and Biobehavioral Reviews

M1 - 104608

ER -

Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this